Deucravacitinib in PG

Novel Treatment of Pyoderma Gangrenosum With Deucravacitinib

The main goal of this study is to see if the study drug called "Deucravacitinib" is safe and effective in treating people with pyoderma gangrenosum (PG).

Study Overview

• Status: Withdrawn
• Conditions: Pyoderma Gangrenosum
• Intervention / Treatment: Drug: Deucravacitinib

• Study Type: Interventional
• Phase: Early Phase 1

Contacts and Locations

Study Locations

• United States
  • New Hampshire
    • Lebanon, New Hampshire, United States, 03576
      • Dartmouth-Hitchcock Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Men and women between the ages of 18-70 years old
• Diagnosed with pyoderma gangrenosum requiring one major and at least 4 minor criteria
• Women must not be pregnant, lactating, or planning pregnancy during the study period
• Women of child-bearing potential must be on birth control for the duration of the treatment period.
• Subjects must agree to the use of at least one of the following contraception methods for the entire duration of the study until at least 30 days after taking their last dose of study drug:
• Women: Hormonal contraception (oral, injections, patch, implant, or vaginal-ring); Spiral (with or without hormones); any sterilization methods; a partner who has had a vasectomy; or sexual abstinence.
• Other acceptable methods of contraception are male or female condoms (with or without spermicide) or a cap, diaphragm, or sponge with spermicide.
• Willing to discontinue topical and/or systemic therapies, with the exception of oral rescue therapy with steroids.
• The wash period for systemic therapies will largely depend on the specific treatment but, in general, will be at least 6 months for biologics and 3 months for other immune- suppressants such as cyclosporine, mycophenolate mofetil, methotrexate, etc. No wash out period is required for topicals.
• Capable and willing to sign Institutional Review Board/IEC-approved written informed consent form in accordance with regulatory and institutional guidelines before the performance of any protocol-related procedures.

Exclusion Criteria:

• Patient under 18 years of age.
• Patients with a history of inflammatory bowel disease.
• Patients on systemic immunosuppressive/immune modulating therapy including: oral steroids, cyclosporine, mycophenolate mofetil, methotrexate, Azathioprine or TNFα inhibitor at time of starting deucravacitinib.
• Patients currently enrolled in another investigational study.
• Patients with a history or evidence of active infection and/or febrile illness within 7 days; or serious infection requiring antibiotic treatment within 30 days
• Hepatitis C virus (HCV): subjects known to be positive for anti-HCV antibody or for HCV RNA detectable by polymerase chain reaction (PCR)
• Hepatitis B virus (HBV): subjects known to be positive for hepatitis B surface antigen or for HBV DNA detectable by PCR
• Human Immunodeficiency Virus (HIV) infection: subjects known to be HIV positive
• History of active or inadequately treated latent tuberculosis (TB)
• Known or suspected systemic or skin autoimmune disorder other than pyoderma gangrenosum
• Any unstable major illness or evidence of unstable condition of major organ systems including psychiatric
• Cancer or history of lymphoproliferative disease within last 5 years; exception is cutaneous basal cell carcinoma or squamous cell carcinoma that has been treated.
• Major surgery within the last 4 weeks
• Live vaccines within the last 60 days
• Leukopenia (absolute WBC count < 3000/mm3); Lymphopenia (ALC < 500/mm3); Neutropenia (ANC < 1000/mm3)
• Thrombocytopenia (platelet count < 100,000/mm3; Anemia (hemoglobin < 9.0g/dL)
• ALT/AST > 3 X ULN and/or Total, unconjugated, and/or conjugated bilirubin > 2 X ULN within 28 days of dosing

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Deucravacitinib; Participants to receive Deucravacitinib 6 mg tablets orally twice daily for 12 weeks.	Drug: Deucravacitinib; 6 mg tablet; Other Names: SOTYKTU

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Physician's Global Assessment (PGA)	PGA will be used for overall assessment of efficacy.	Baseline; Days 8, 15, 29, 57, and 85; Follow up Day 115
Change from baseline in ulcer size measured by calculating the area of the ulcers in centimeters squared using a digital application.	imitoAG application for mobile devices will be used to calculate the dimensions of the ulcers in centimeters to determine if the size of the ulcers is changed by the treatment.	Baseline; Days 8, 15, 29, 57, and 85; Follow up Day 115

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The percentage of patients needing rescue therapy from baseline to Day 115	Determining the number of participants that required rescue therapy while on study.	Baseline through Day 115

Collaborators and Investigators

• Sponsor: Dartmouth-Hitchcock Medical Center
• Collaborators: Bristol-Myers Squibb
• Investigators: Principal Investigator: Brian J. Simmons, MD, Dartmouth-Hitchcock Medical Center

Study record dates

Study Major Dates

• Study Start (Actual): April 29, 2024
• Primary Completion (Actual): April 29, 2024
• Study Completion (Actual): April 29, 2024

Study Registration Dates

• First Submitted: March 20, 2023
• First Submitted That Met QC Criteria: April 6, 2023
• First Posted (Actual): April 20, 2023

Study Record Updates

• Last Update Posted (Actual): June 27, 2025
• Last Update Submitted That Met QC Criteria: June 24, 2025
• Last Verified: June 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Skin Ulcer; Skin Diseases, Vascular; Pyoderma; Pyoderma Gangrenosum; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Dermatologic Agents; Protein Kinase Inhibitors; Deucravacitinib
• Other Study ID Numbers: STUDY02001753

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No